Aerpio Pharmaceuticals, (Nasdaq: ARPO), the stock dipped -40.89% to $1.33 in the After-market session, as Razuprotafib met its primary efficacy endpoint at 28 days in Aerpio’s double-blind Phase 2 trial in patients with elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension.
Compared to the monotherapy group, razuprotafib did not show any statistically significant change in IOP at Day 28 when tested on the two groups separately.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The study aimed to assess the safety and efficacy of topical ocular formulations of razuprotafib as an adjunct to the standard of care latanoprost.
A total of 194 patients underwent a 28-day washout cycle. It was randomized to undergo 0.005 percent latanoprost ophthalmic solution once daily with placebo-based adjunctive treatment, 40 mg/ml razuprotafib once daily, or 40 mg/ml razuprotafib twice daily, in a 1:1:1 fashion. The key endpoint of the analysis by latanoprost monotherapy groups was a mean diurnal IOP for the treatment of razuprotafib at 28 days.